Clinical Trials Logo

Filter by:
NCT ID: NCT00838903 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Start date: February 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.

NCT ID: NCT00661206 Active, not recruiting - Clinical trials for Coronary Artery Disease

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

ISAR-SAFE
Start date: September 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether a 6 month duration of clopidogrel therapy after DES implantation is not inferior to that of a 12 month therapy.

NCT ID: NCT00545779 Completed - Clinical trials for Post-Menopausal Osteoporosis

BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.

Start date: December 2006
Phase: Phase 4
Study type: Interventional

This single arm study will assess patient preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis. Patients currently on a daily or weekly regimen of bisphosphonate therapy (alendronate or risedronate) will answer a questionnaire to identify patients who may benefit from a monthly Bonviva regimen. Eligible patients will then discontinue their present bisphosphonate treatment, and switch to monthly Bonviva 150mg po. At the beginning and end of Bonviva treatment, all patients will complete an Osteoporosis Patient Satisfaction Questionnaire. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00430352 Completed - Clinical trials for Non-Hodgkin's Lymphoma

MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Start date: September 2006
Phase: Phase 4
Study type: Interventional

This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.

NCT ID: NCT00407095 Completed - Clinical trials for Advanced Stage Parkinson's Disease

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

Start date: August 2007
Phase: Phase 3
Study type: Interventional

This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.